Cargando…

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly

Age is one of the strongest predictors of cardiovascular disease (CVD) risk. Treatment with statins can significantly reduce CVD events and mortality in both primary and secondary prevention. Yet despite the high CVD risk among the elderly, there is underutilization of statins in this population (ie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Sydney B, Blaha, Michael J, Blumenthal, Roger S, Michos, Erin D
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066250/ https://www.ncbi.nlm.nih.gov/pubmed/21472089 http://dx.doi.org/10.2147/CIA.S8101

Ejemplares similares

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
por: Narla, Venkata, et al.
Publicado: (2009)

Hoping rosuvastatin for primary prevention of cardiovascular events, are all statins similar and are we ready for statinizing the globe?
por: Kumar, Arun H. S.
Publicado: (2016)

Income disparity and utilization of cardiovascular preventive care services among U.S. adults
por: Shahu, Andi, et al.
Publicado: (2021)

Non-cardiovascular effects associated with statins
por: Desai, Chintan S, et al.
Publicado: (2014)

Coronary artery calcium and atherosclerotic cardiovascular disease risk in women with early menopause: The Multi-Ethnic Study of Atherosclerosis (MESA)
por: Chu, Jian H., et al.
Publicado: (2022)

A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin
por: Kim, Se Yong, et al.
Publicado: (2015)

Personalized rosuvastatin therapy in problem patients with partial statin intolerance
por: Shek, Aleksandr B., et al.
Publicado: (2018)

Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention
por: Duffy, Eamon Y., et al.
Publicado: (2021)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
por: Masadeh, Majed, et al.
Publicado: (2012)

Statins for primary cardiovascular prevention in the elderly
por: Pedro-Botet, Juan, et al.
Publicado: (2015)

Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
por: Wang, Zhen, et al.
Publicado: (2013)

Opportunities to improve cardiovascular health in the new American workplace
por: Duffy, Eamon Y., et al.
Publicado: (2020)

Nondietary Cardiovascular Health Metrics With Patient Experience and Loss of Productivity Among US Adults Without Cardiovascular Disease: The Medical Expenditure Panel Survey 2006 to 2015
por: Tibuakuu, Martin, et al.
Publicado: (2020)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease’s ‘ABC’s Approach
por: Feldman, David I., et al.
Publicado: (2020)

Cost-Effectiveness of Coronary Artery Calcium Testing for Coronary Heart and Cardiovascular Disease Risk Prediction to Guide Statin Allocation: The Multi-Ethnic Study of Atherosclerosis (MESA)
por: Roberts, Eric T., et al.
Publicado: (2015)

Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins
por: Morales-Villegas, Enrique C., et al.
Publicado: (2011)

Rosuvastatin-Induced Dizziness and Pruritus: A Case Report and Summary of Statin-Associated Dizziness and Pruritus
por: Malik, Sara, et al.
Publicado: (2022)

High-Intensity Statin With Severe Consequences: A Case of Non-autoimmune Rosuvastatin-Induced Myonecrosis
por: Hassan, Mariam, et al.
Publicado: (2022)

Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial
por: Camilleri, Eleonora, et al.
Publicado: (2023)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
por: Yang, Yujin, et al.
Publicado: (2021)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Sex Differences in the Age of Diagnosis for Cardiovascular Disease and Its Risk Factors Among US Adults: Trends From 2008 to 2017, the Medical Expenditure Panel Survey
por: Okunrintemi, Victor, et al.
Publicado: (2020)

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
por: Luvai, Ahai, et al.
Publicado: (2012)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome
por: Umrani, Salman, et al.
Publicado: (2020)

Regulatory Effects of Statins on SIRT1 and Other Sirtuins in Cardiovascular Diseases
por: Khayatan, Danial, et al.
Publicado: (2022)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

Statins in risk-reduction and treatment of cancer
por: Barbalata, Cristina I, et al.
Publicado: (2020)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome
por: Kumar, Besham, et al.
Publicado: (2019)

Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
por: Calza, Leonardo
Publicado: (2009)

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies
por: Martin, P., et al.
Publicado: (2016)

Current Perspectives on rosuvastatin
por: Hu, Miao, et al.
Publicado: (2013)

Narrowing Sex Differences in Lipoprotein Cholesterol Subclasses Following Mid‐Life: The Very Large Database of Lipids (VLDL‐10B)
por: Swiger, Kristopher J., et al.
Publicado: (2014)

Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention
por: Kohli, Payal, et al.
Publicado: (2014)

Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England
por: Ueda, Peter, et al.
Publicado: (2018)

Pleotropic effects of statins: the dilemma of wider utilization of statin
por: Choudhary, Ambika, et al.
Publicado: (2023)

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
por: Viigimaa, Margus, et al.
Publicado: (2010)

Oral use of “Low and Slow” Rosuvastatin with Co-Enzyme Q(10) in patients with Statin-Induced Myalgia: Retrospective case review
por: Vidyarthi, Madhurima, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pfs7vod007qhepg0t5nnm7k8sp